文章核心观点 - 公司第二季度销售额超出预期,但利润因一次性成本而低于预期 [1][2][3][4] - 公司上调全年销售指引,但下调利润预测 [5][6] 销售情况 - 公司医药和医疗器械业务销售额同比增长4%,达到224.5亿美元,超出分析师预期的223.8亿美元 [3] - 公司净利润为46.9亿美元,低于分析师预期的56.6亿美元,但剔除一次性成本后调整后净利润为68.4亿美元,超出预期的65.9亿美元 [4] 全年指引 - 公司上调全年销售指引至892-896亿美元,高于之前的887-891亿美元 [6] - 但公司下调全年调整每股收益预测至9.97-10.07美元,低于之前的10.57-10.72美元 [6] - 分析师预测公司全年销售额为885.8亿美元,调整每股收益为10.42美元 [7]

业绩总结 - 公司2024年第二季度销售额达到224亿美元，较去年同期增长4.3%[25] - 调整后的每股收益较去年同期增长10.2%[38] - 创新药业务在第二季度实现了9.0%的调整后运营增长[39] - Johnson & Johnson MedTech部门2024年第二季度调整前税前收入为8.4亿美元[56] 用户数据 - 全球销售增长率为2.2%，美国为5.7%，国际市场为-1.3%[47] - Orthopaedics部门销售额为2,312百万美元，增长率为2.1%至3.3%[49] - Cardiovascular部门销售额为1,873百万美元，增长率为15.6%至18.0%[49] - Vision Surgery部门销售额为1,285百万美元，增长率为-1.7%至0.8%[49] 未来展望 - 预计2024年全年调整后运营每股收益为10.05美元[74] - 预计2024年全年调整后运营销售增长率为5.5%至6.0%[76] - 预计2024年全年调整后每股收益为9.97美元至10.07美元[77] 新产品和新技术研发 - 公司在2024年7月17日发布的信息中，BALVERSA药物获得了美国全面批准[103]

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.71 per share. This compares to earnings of $2.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.06%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.64 per share when it actually produced earnings of $2.71, delivering a surprise of 2.65%.Over ...

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) SECOND QUARTER Percent Change | --- | --- | --- | --- | --- | --- | |---------------------------------------|---------|--------|-------|------------|----------| | Sales to customers by geographic area | 2024 | 2023 | Total | Operations | Currency | | U.S. | $12,569 | 11,657 | 7.8 % | 7.8 | — | | Europe | 5,214 | 5,131 | 1.6 | 3.4 | (1.8) | | Western Hemisphere excluding U.S. | 1,212 | 1,136 | 6.7 | 22.6 ...

Loading...Loading...Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours.The stock is down 5.56% over the past year, -4.16% YTD.Let’s look at what the charts indicate for Johnson & Johnson stock and how the stock currently maps against Wall Street estimates.Johnson & Johnson Technical Setup Ahead Of Q2 Earnings Johnson & Johnson stock is exhibiting a strongly bullish trend, as its ...

Loading...Loading...Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period. Johnson & Johnson is expected to post revenue of $22.29 billion, compared to $25.53 billion a year earlier, according to data from Benzinga Pro.Emergent BioSolutions Inc EBS, through its subsidiary Emergent Manufactu ...

GERMANY - 2024/02/16: In this photo illustration, a Johnson & Johnson logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with the consensus estimates of $22.4 billion and $2.71, respectively. J&J will likely ...

Johnson & Johnson (JNJ) will report its second-quarter 2024 earnings on Jul 17. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $22.38 billion and $2.71 per share, respectively. Earnings estimates for JNJ have declined from $10.64 per share to $10.50 per share for 2024 and from $10.92 per share to $10.86 per share for 2025 over the past 60 days.JNJ Estimate MovementImage Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been ...

SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Got ...

They don't have the most exciting businesses, but they have a lot to offer nonetheless.Healthcare never sleeps. There is always demand for medical services, regardless of the state of the economy. Companies that offer these necessary goods and are innovative enough to keep up with the changing trends in the sector tend to last. That describes Johnson & Johnson (JNJ 0.12%) and Medtronic (MDT -0.15%) well. Both are among the largest healthcare companies in the world, have proven innovative abilities, and have ...